Samsung Electronics
Search results
Samsung Biologics builds stronger connections through bolstered CDO capabilities and continuous expansion | Highlights from BIO 2024. Minimize risk, maximize success: identify high-potential candidates with a robust developability assessment platform with scope expansions.
Samsung Biologics Co., Ltd. is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.
Mar 31, 2023 · Find all Investor Relation materials, including our earnings release, stock chart, public disclosures, annual and business reports, and audited financial statements.
3 days ago · INCHEON, South Korea, July 01, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application ...
Samsung Biologics secured a massive $1.06 billion deal from a U.S. drug maker, the biopharmaceutical contract manufacturer said in a regulatory filing on Tuesday. The deal is the largest ever ...
2 days ago · Samsung Bioepis vice-president and regulatory affairs team leader Byoung In Jung stated: “The FDA approval of PYZCHIVA as a biosimilar to Stelara is an important milestone for patients living with inflammatory conditions, as biosimilars can offer more choice and access to biologic treatments. “In addition, biosimilars have a potential to reduce the financial burden of healthcare systems, especially in the US where biologics account for more than 46% of the annual drug spending.” ...
Jan 28, 2022 · Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and bioanalytical testing services.
Nov 18, 2020 · Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.
Mar 31, 2023 · Samsung Biologics is a fully integrated CDMO with qualified and highly innovative contract development, contract manufacturing, and biosafety testing services.
Incheon, S. Korea, July 18, 2023 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report.
